Cinclus Pharma Holding AB (OSTO:CINPHA) Operating Income: kr-292.02 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CINPHA Cinclus Pharma Holding AB OSTO:CINPHA
2 GF Score
Price kr13.20
! 5 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Operating Income?

Cinclus Pharma Holding AB OSTO:CINPHA +0.76% 2 Operating Income is kr-292.02 Mil as of Jun. 2026. GuruFocus rates OSTO:CINPHA with a GF Score™ of 2/100. The stock has 5 warning signs investors should review.

Cinclus Pharma Holding AB's Operating Income for the three months ended in Jun. 2026 was kr-95.03 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was kr-292.02 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cinclus Pharma Holding AB's Operating Income for the three months ended in Jun. 2026 was kr-95.03 Mil. Cinclus Pharma Holding AB's Revenue for the three months ended in Jun. 2026 was kr1.77 Mil. Therefore, Cinclus Pharma Holding AB's Operating Margin % for the quarter that ended in Jun. 2026 was -5,381.14%.

Cinclus Pharma Holding AB's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cinclus Pharma Holding AB's annualized ROC % for the quarter that ended in Jun. 2026 was -252.68%. Cinclus Pharma Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -4,682.77%.


Cinclus Pharma Holding AB  (OSTO:CINPHA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cinclus Pharma Holding AB's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-380.124 * ( 1 - 0% )/( (153.286 + 147.591)/ 2 )
=-380.124/150.4385
=-252.68 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=511.639 - 29.523 - ( 475.849 - max(0, 173.958 - 502.788+475.849))
=153.286

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=424.54 - 41.401 - ( 387.916 - max(0, 181.017 - 416.565+387.916))
=147.591

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cinclus Pharma Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-380.124/( ( (8.556 + max(-123.574, 0)) + (7.679 + max(-129.464, 0)) )/ 2 )
=-380.124/( ( 8.556 + 7.679 )/ 2 )
=-380.124/8.1175
=-4,682.77 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.418 + 0 + 0.0040000000000191) - (29.523 + 0 + 95.473)
=-123.574

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.0040000000000191) - (41.401 + 0 + 88.067)
=-129.464

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Cinclus Pharma Holding AB's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-95.031/1.766
=-5,381.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cinclus Pharma Holding AB Operating Income Related Terms


Cinclus Pharma Holding AB Operating Income Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Operating Income Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
-84.27 -210.73 -200.28 -168.93 -198.18

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.91 -44.12 -62.01 -90.85 -95.03
OSTO:CINPHA
2GF Score
Cinclus Pharma Holding AB OSTO:CINPHA
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-292.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of kr-292.02 Mil mean?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a Operating Income of kr-292.02 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Operating Income too high?
Cinclus Pharma Holding AB's current Operating Income is kr-292.02 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Operating Income compare to ZTS?
Cinclus Pharma Holding AB's Operating Income of kr-292.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Operating Income is kr-292.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (OSTO:CINPHA) has a current Operating Income of kr-292.02 Mil. The current Operating Income is kr-292.02 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 2/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Cinclus Pharma Holding AB (OSTO:CINPHA), the current Operating Income is kr-292.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
2GF Score

Get the complete analysis for OSTO:CINPHA

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr13.20
Price